

Fluoroquinolone-Resistant and Extended-Spectrum β -Lactamase-Producing *Escherichia coli* Infections in Patients with Pyelonephritis, United States¹

David A. Talan, Sukhjit S. Takhar, Anusha Krishnadasan, Fredrick M. Abrahamian, William R. Mower, Gregory J. Moran; EMERGENCY ID Net Study Group

Medscape **ACTIVITY** EDUCATION

This activity has been planned and implemented through the joint providership of Medscape, LLC and *Emerging Infectious Diseases*. Medscape, LLC is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE) and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 **AMA PRA Category 1 Credit(s)**[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at <http://www.medscape.org/journal/eid>; and (4) view/print certificate. For CME questions, see page 1701.

Release date: August 12, 2016; Expiration date: August 12, 2017

Learning Objectives

Upon completion of this activity, participants will be able to:

- Assess recommendations regarding the treatment of pyelonephritis
- Distinguish the rates of fluoroquinolone resistance and extended-spectrum β -lactamase (ESBL) production among patients with pyelonephritis in the current study
- Evaluate risk factors for fluoroquinolone resistance in the current study
- Evaluate risk factors for ESBL production in the current study

CME Editor

Rhonda Ray, PhD, Copyeditor, *Emerging Infectious Diseases*. Disclosure: Rhonda Ray, PhD, has disclosed no relevant financial relationships.

CME Author

Charles P. Vega, MD, Clinical Professor of Family Medicine, University of California, Irvine. Disclosure: Charles P. Vega, MD, has disclosed the following financial relationships: served as an advisor or consultant for Allergan, Inc.; McNeil Consumer Healthcare; served as a speaker or a member of a speakers bureau for Shire Pharmaceuticals.

Authors

Disclosures: **David A. Talan, MD**, has disclosed the following relevant financial relationships: served as an advisor or consultant for Allergan, Inc.; Cempira; served as a speaker or a member of a speakers bureau for Allergan, Inc.; Merck; received grants for clinical research from Merck. **Sukhjit S. Takhar, MD; Anusha Krishnadasan, PhD; and William R. Mower, MD, PhD**, have disclosed no relevant financial relationships. **Fredrick M. Abrahamian, DO**, has disclosed the following relevant financial relationships: served as an advisor or consultant for Grifols; Cempira; Summitt Therapeutics; Tetrphase Pharmaceuticals; Janssen; Seqirus; served as a speaker or a member of a speakers bureau for Merck; Actavis; Medicines Company; received grants for clinical research from Merck; Cempira; owns stock, stock options, or bonds from Gilead. **Gregory J. Moran, MD**, has disclosed the following relevant financial relationships: received grants for clinical research from Cempira; Allergan.

¹Preliminary results of this research were presented at the 2014 IDWeek Meeting, Philadelphia, PA, USA, October 8–12, 2014.

For 2013–2014, we prospectively identified US adults with flank pain, temperature $\geq 38.0^{\circ}\text{C}$, and a diagnosis of acute pyelonephritis, confirmed by culture. Cultures from 453 (86.9%) of 521 patients grew *Escherichia coli*. Among *E. coli* isolates from 272 patients with uncomplicated pyelonephritis and 181 with complicated pyelonephritis, prevalence of fluoroquinolone resistance across study sites was 6.3% (range by site 0.0%–23.1%) and 19.9% (0.0%–50.0%), respectively; prevalence of extended-spectrum β -lactamase (ESBL) production was 2.6% (0.0%–8.3%) and 12.2% (0.0%–17.2%), respectively. Ten (34.5%) of 29 patients with ESBL infection reported no exposure to antimicrobial drugs, healthcare, or travel. Of the 29 patients with ESBL infection and 53 with fluoroquinolone-resistant infection, 22 (75.9%) and 24 (45.3%), respectively, were initially treated with in vitro inactive antimicrobial drugs. Prevalence of fluoroquinolone resistance exceeds treatment guideline thresholds for alternative antimicrobial drug strategies, and community-acquired ESBL-producing *E. coli* infection has emerged in some US communities.

Escherichia coli, the predominant cause of community-acquired urinary tract infection (UTI) worldwide, is increasingly resistant to available antimicrobial drugs. In the United States, in vitro resistance of *E. coli* to trimethoprim/sulfamethoxazole (TMP/SMX) became prevalent in the 1990s (1). Over the past decade, fluoroquinolone resistance rates have increased to $>10\%$ in some surveys (2,3).

In many parts of the world, *E. coli* fluoroquinolone resistance rates are $>20\%$ among patients with community-acquired uncomplicated UTI and $>50\%$ among patients with complicated infections (4). In addition, infections resulting from extended-spectrum β -lactamase (ESBL)-producing *E. coli* and other *Enterobacteriaceae* are becoming increasingly common in these same areas and are associated with sequence type (ST) 131, a globally disseminated, multidrug-resistant clone that frequently produces CTX-M-15 ESBL. These *E. coli* isolates are generally resistant to cephalosporins and often to other antimicrobial drug classes. In North America, ESBL-producing *E. coli* infections have occurred predominantly in patients with healthcare exposure and have not become prevalent as a cause of community-acquired infections (5–8).

The 2010 international treatment guidelines of the Infectious Disease Society of America (IDSA) recommend for acute

uncomplicated pyelonephritis a fluoroquinolone and an initial dose of an agent from another antimicrobial drug class (e.g., ceftriaxone or gentamicin) if the fluoroquinolone resistance rate is $>10\%$ (9). For uncomplicated cystitis, the guidelines discourage use of an antimicrobial drug if its resistance rate is $>20\%$. The guidelines do not address a scenario in which ESBL-producing uropathogens have become prevalent among patients with community-acquired infections. Use of antimicrobial drugs for which the uropathogen shows in vitro resistance has been associated with substantially reduced response rates (1,10,11), which can lead to serious consequences, particularly for patients with pyelonephritis. Given rapid changes in global resistance patterns and a lack of recent active and prospective surveillance of community-acquired UTI in the United States, the extent to which the prevalence of fluoroquinolone resistance has increased and multidrug-resistant ESBL-producing strains have emerged in the community is unknown.

We sought to determine the prevalence of *E. coli* antimicrobial resistance among patients with acute pyelonephritis who sought care at a US emergency department (ED)-based sentinel research network. We focused on fluoroquinolone-resistant and ESBL-producing isolates from these patients and examined risk factors for antimicrobial drug resistance.

Methods

Participants

We recruited adults seeking care in EMERGENCY ID NET, a network of 10 university-affiliated urban US EDs (12). All 10 study sites (online Technical Appendix, <http://www-wnc.cdc.gov/EID/article/22/9/16-0148-Techapp1.pdf>) provided institutional review board approval.

We enrolled patients ≥ 18 years of age who sought care during July 2013–December 2014 and had flank pain or costovertebral tenderness; temperature $\geq 38.0^{\circ}\text{C}$ (100.4°F) measured by any method (i.e., oral, rectal, or axillary); and a presumptive diagnosis of acute pyelonephritis (i.e., patient received treatment for this infection during ED visit or was prescribed treatment at discharge). All sites conducted an audit to compare characteristics of enrolled and nonenrolled eligible patients to estimate case-finding sensitivity and detect enrollment biases (online Technical Appendix).

Design and Measurements

We conducted a cross-sectional study by using a convenience sample of prospectively identified patients. ED physicians or study coordinators who used standardized forms at the time of care collected the following: demographic characteristics (i.e., age, sex, race, ethnicity); symptom duration; urinary tract abnormalities; UTI within the previous year; concurrent and immunocompromising conditions; antimicrobial drug use within the previous 2 and 60 days; a fluoroquinolone- or

Author affiliations: David Geffen School of Medicine at the University of California, Los Angeles (UCLA), Los Angeles, California, USA (D.A. Talan, A. Krishnadasan, F.M. Abrahamian, W.R. Mower, G.J. Moran); Olive View–UCLA Medical Center, Los Angeles (D.A. Talan, A. Krishnadasan, F.M. Abrahamian, G.J. Moran); Brigham and Women's Hospital, Boston, Massachusetts, USA (S.S. Takhar); Harvard Medical School, Boston (S.S. Takhar); Ronald Reagan Medical Center, Los Angeles (W.R. Mower)

DOI: <http://dx.doi.org/10.3201/eid2209.160148>

ceftriaxone-resistant UTI within the previous 90 days and 1 year; long-term care residence; hospitalization; travel outside North America within the previous 90 days; illness severity; disposition; and treatments provided. The study population consisted of patients with urine specimens that grew a single uropathogen at $\geq 10^4$ CFU/mL. We defined a uropathogen as an organism known to be associated with UTI; among possible pathogens, we found *E. coli*, *Klebsiella*, *Proteus*, *Pseudomonas*, *Citrobacter*, *Enterobacter*, and *Salmonella* species; *Staphylococcus aureus* or *S. saprophyticus*; and *Enterococcus* and *Aerococcus* species. If a urine specimen grew >1 organism, we considered it to be contaminated and excluded it. We also excluded specimens that grew *Lactobacillus*, non-saprophyticus coagulase-negative *Staphylococcus*, or *Corynebacteria* species; or α - or β -hemolytic streptococci.

Patients' urine specimens were collected in sterile containers by mid-stream clean-catch technique (91.4%), urethral catheterization (5.8%), and other techniques (e.g., sample from collection bag [2.7%] or suprapubic aspirate [0.2%]). Laboratories determined MICs by using automated susceptibility testing with VITEK commercial panels (bioMérieux, Marcy l'Etoile, France) at 7 sites; Microscan (Dade Behring, Inc., Sacramento, CA, USA) at 2 sites; and Phoenix Instrument System (Becton Dickinson, Franklin Lakes, NJ, USA) at 1 site, according to manufacturer instructions.

Each site used *E. coli* antimicrobial drug resistance breakpoints based on MIC breakpoints ($\mu\text{g/mL}$) of the Clinical and Laboratory Standards Institute (Wayne, PA, USA) as follows: ampicillin ≥ 32 ; TMP/SMX $\geq 4/76$; ceftazidime ≥ 8 ; ceftriaxone ≥ 4 ; cefotaxime ≥ 4 ; ciprofloxacin ≥ 4 ; levofloxacin ≥ 8 ; ertapenem ≥ 2 ; and imipenem ≥ 4 (13). We report resistance rates for antimicrobial drugs included in the study site laboratories' standard susceptibility testing panel. In 2010, the Clinical and Laboratory Standards Institute changed breakpoints for cephalosporins, aztreonam, and carbapenems. We provided Etests (bioMérieux) for ceftriaxone and imipenem to sites that had not yet updated automated susceptibility testing systems to enable these sites to use the new breakpoints. We considered *Enterobacteriaceae* isolates that were nonsusceptible to ceftriaxone (i.e., MIC >1 $\mu\text{g/mL}$) to be potentially ESBL producing (13). The sites shipped these isolates to a reference laboratory to confirm speciation, ESBL production, and molecular characterization (online Technical Appendix).

We classified patients as having complicated pyelonephritis if they were pregnant or male or had a current or pre-existing functional or anatomic urinary tract abnormality or current immunocompromising condition. Possible preexisting urinary tract abnormalities were history of kidney stones, genitourinary procedures within the past 30 days, prostatic pathology, bladder catheter within the past 30 days, neurogenic urinary retention, ureteral stricture, duplicated collecting system, renal or bladder cancer, renal transplant, ureteral

diversion, vesico-ureteral reflux, single kidney, and nephrostomy tubes. Immunocompromising conditions were diabetes, active cancer, systemic corticosteroid use, current use of other immunosuppressants, chronic debilitating condition, chronic renal insufficiency or failure, and HIV infection. We identified current complicating features on the basis of clinical findings or laboratory studies in the ED; possible complications were pregnancy, diabetes, bladder catheter, ureteral stent, percutaneous nephrostomy tube, prostatitis, nephrolithiasis, renal or perirenal abscess, and urinary retention. We recorded history of chronic debilitating illness, such as chronic obstructive pulmonary disease or heart or hepatic failure, but did not assign such illness as a criterion for complicated infection. We classified patients without criteria for complicated pyelonephritis as having uncomplicated pyelonephritis. We defined healthcare-associated infections as those in patients hospitalized or residing in a long-term care facility within the previous 90 days; other patients were classified as having community-acquired infections.

Statistical Analysis

To manage the study data, we used REDCap electronic-data capture tools hosted by the University of California, Los Angeles, CA, USA (14). We used SAS Version 9.3 (Cary, NC, USA) and Microsoft Excel 2013 (Redmond, WA, USA) to analyze data and used descriptive statistics to summarize patient characteristics and resistance prevalence. We calculated relative risks and 95% CIs to determine associations between epidemiologic and clinical characteristics and presence or absence of fluoroquinolone-resistant and ESBL-producing *E. coli* infections.

Results

Of 817 enrolled patients with acute pyelonephritis, 793 (97.1%) submitted a urine culture. Of those 793 patients, 272 (34.3%) were excluded from analysis: 149 (18.8%) had no culture growth; 74 (9.3%) grew ≥ 1 contaminant; 17 (2.1%) grew ≥ 1 isolate at $<10^4$ CFU/mL; 25 (3.2%) grew >1 organism at 10^4 CFU/mL; and 7 (0.9%) had no fever. The study population consisted of 521 patients who grew 1 uropathogen at $\geq 10^4$ CFU/mL. The case finding audit revealed a 66% enrollment of eligible patients. Enrolled and nonenrolled patients were similar for most characteristics, including *E. coli* susceptibility rates to TMP/SMX, ceftriaxone, and fluoroquinolones (online Technical Appendix).

Among the 521 study patients, median age was 37 (range 18–88, interquartile range 26–52) years; 455 (87.3%) were female (Table 1). Most (446 [85.6%]) patients had a community-acquired infection; 74 (14.2%) had a healthcare-associated infection (70 with hospitalization and 9 with nursing home residence in the previous 90 days). A total of 286 (54.9%) patients had uncomplicated pyelonephritis; 235 (45.1%) had complicated pyelonephritis.

Table 1. Epidemiologic, clinical, and laboratory characteristics of 521 US emergency department patients with acute uncomplicated and complicated pyelonephritis, July 2013–December 2014*

	Value		
	Total patients, N = 521	Uncomplicated, n = 286	Complicated, n = 235
Age, median y (IQR; range)	37 (26–52; 18–88)	30 (23–41; 18–79)	50 (36–58; 19–88)
Symptom duration, median d (IQR; range)	3.0 (2–5; 0–30)	3.0 (2–5; 0–30)	3.0 (2–5; 0–30)
Initial ED temperature, °C (IQR; range)	38.9 (38.4–39.4; 38.0–43.0)	38.9 (38.4–39.4; 38.0–40.3)	39.0 (38.4–39.4; 38.0–43.0)
Sex			
F	455 (87.3)	286 (100.0)	169 (71.9)
M	66 (12.7)	0 (0)	66 (28.1)
Race/ethnicity			
White/Hispanic	372 (71.4)	191 (66.8)	181 (77.0)
Black	119 (22.8)	76 (26.6)	43 (18.3)
Asian/Pacific Islander	22 (4.2)	15 (5.2)	7 (3.0)
Other	18 (3.5)	11 (3.9)	7 (3.0)
Unknown	5 (1.0)	3 (1.0)	2 (0.9)
Hispanic ethnicity			
Yes	281 (53.9)	155 (54.2)	126 (53.6)
No	233 (44.7)	126 (44.1)	107 (45.5)
Unknown	7 (1.3)	5 (1.7)	2 (0.9)
Antimicrobial drugs taken			
Within past 60 d	125 (24.0)	49 (17.1)	76 (32.3)
Within past 2 d	36 (6.9)	15 (5.2)	21 (8.9)
Healthcare-associated illness†	74 (14.2)	18 (6.3)	56 (23.8)
Complicating feature			
Concurrent condition	131 (25.1)	0 (0)	131 (55.7)
History of UTA	116 (22.3)	0 (0)	116 (49.4)
Current feature	61 (11.7)	0 (0)	61 (26.0)
UTIs within past year‡			
0	334 (64.5)	196 (68.8)	138 (59.2)
1	86 (16.6)	46 (16.1)	40 (17.2)
2	428 (8.1)	23 (8.1)	19 (8.2)
≥3	56 (10.8)	20 (7.0)	36 (15.5)
Travel outside North America within past 90 d§	17/520 (3.3)	8/286 (2.8)	9/234 (3.8)
Prior UTI caused by fluoroquinolone-resistant <i>E. coli</i>			
Within past year	16 (3.1)	4 (1.4)	12 (5.1)
Within past 90 d	14 (2.7)	2 (0.7)	12 (5.1)
Prior UTI caused by ceftriaxone-resistant <i>E. coli</i>			
Within past year	9 (1.7)	2 (0.7)	7 (3.0)
Within past 90 d	6 (1.2)	1 (0.3)	5 (2.1)
Severity of illness¶			
Mild	66 (12.7)	34 (11.9)	32 (13.6)
Moderate	267 (51.2)	156 (54.5)	111 (47.2)
Severe	188 (36.1)	96 (33.6)	92 (39.1)
Disposition			
Ward	240 (46.1)	100 (35.0)	140 (59.6)
MCA	40 (7.7)	13 (4.5)	27 (11.5)
Home	239 (45.9)	172 (60.1)	67 (28.5)
AMA	2 (0.4)	1 (0.3)	1 (0.4)

*Values are given as no. (%) except as indicated. AMA, left against medical advice; *E. coli*, *Escherichia coli*; ED, emergency department; IQR, interquartile range; MCA, monitored care admission; UTA, urinary tract abnormality; UTI, urinary tract infection.

†Hospitalized or residing in a long-term care facility within past 90 days.

‡Percentages were calculated with UTI information available for 518 patients, 285 of whom had uncomplicated cases and 233 had complicated cases.

§Percentages were calculated with information available for 520 patients, 286 of whom had uncomplicated cases and 234 had complicated cases.

¶Mild indicates illness that does not affect patient's normal activities; moderate partially affects normal activities but does not confine patient to house or bed; severe affects activities considerably, such as confining patient to house or bed.

Of types of uropathogens in patients with uncomplicated and complicated pyelonephritis (Table 2), *E. coli* accounted for infections in 453 (86.9%) patients; 272 (60.0%) of the infections were uncomplicated, and 181 (40.0%) were complicated. Among the 286 patients with uncomplicated infections, *E. coli* accounted for 95.1%; among the 235 patients with complicated infections, *E. coli* accounted for 77.0% (Table 2).

E. coli antimicrobial drug resistance rates among patients with complicated pyelonephritis tended to be higher than rates for patients with uncomplicated cases, except for TMP/SMX (Table 3). Among all patients, *E. coli* resistance rates varied by drug: ampicillin, 57.2% (259/453); TMP/SMX, 36.4% (165/453); gentamicin, 9.9% (43/436); cefazolin, 14.2% (52/367); ceftriaxone, 7.7% (35/453); levofloxacin, 10.2% (33/325); and ciprofloxacin, 12.1% (48/397). Among

Table 2. Uropathogens identified among US emergency department patients with acute uncomplicated and complicated pyelonephritis, July 2013–December 2014

Uropathogen	No. (%)		
	Total, N = 521	Uncomplicated cases, n = 286	Complicated cases, n = 235
<i>Escherichia coli</i>	453 (86.9)	272 (95.1)	181 (77.0)
<i>Staphylococcus saprophyticus</i>	2 (0.4)	2 (0.7)	0 (0)
<i>Staphylococcus aureus</i>	4 (0.8)	0 (0)	4 (1.7)
<i>Proteus</i> sp.	4 (0.8)	3 (1.0)	1 (0.4)
<i>Enterobacter</i> sp.	5 (1.0)	1 (0.3)	4 (1.7)
<i>Klebsiella pneumoniae</i>	25 (4.8)	4 (1.4)	21 (8.9)
<i>Enterococcus</i> sp.	12 (2.3)	0 (0)	12 (5.1)
<i>Pseudomonas</i> sp.	7 (1.3)	0 (0)	7 (3.0)
Group B streptococcus	2 (0.4)	1 (0.3)	1 (0.4)
Other*	5 (1.0)	2 (0.7)	3 (1.3)

*Other pathogens were 2 *Aerococcus urinae*, 2 *Citrobacter koseri*, and 1 *Salmonella* species.

53 fluoroquinolone-resistant isolates, 8 (15.1%) were susceptible to ampicillin, 34 (64.2%) to gentamicin, and 27 (50.9%) to ceftriaxone. Of 46 isolates tested for susceptibility to cefazolin, 19 (41.3%) were susceptible; all 48 (100%) isolates tested were susceptible to a carbapenem. *E. coli* antimicrobial drug resistance rates for patients with uncomplicated and complicated pyelonephritis varied by study site (online Technical Appendix Tables 2, 3).

Among patients with uncomplicated pyelonephritis, 17 (6.3%) of 272 *E. coli* isolates were resistant to fluoroquinolone. The range of prevalence by site was 0.0%–23.1%; for 2 sites, prevalence was >10% (Figure 1; online Technical Appendix Tables 2, 3). Among patients with complicated pyelonephritis, 36 (19.9%) of 181 *E. coli* isolates showed fluoroquinolone resistance. The range of prevalence by site was 0.0%–50.0%; 8 sites had a prevalence >10%, 4 of which had a prevalence ≥20%. We found fluoroquinolone resistance associated with complicated *E. coli* infection, prior use of antimicrobial drugs and fluoroquinolone, hospital admission, and prior UTI resulting from a fluoroquinolone- or ceftriaxone-resistant organism (Table 4).

Among patients with uncomplicated pyelonephritis, ESBL production was found in 7 (2.6%) of 272 *E. coli* isolates; range by study site was 0.0%–8.3% (Figure 2; online Technical Appendix Tables 2, 3). Among patients with complicated pyelonephritis, ESBL production was found in

22 (12.2%) of 181 *E. coli* isolates; range by site was 0.0%–17.2% (Figure 2; online Technical Appendix Tables 2, 3). Frequencies of ESBL-producing *E. coli* isolates were higher among patients with antimicrobial drug resistance risk factors than among those without these factors (Table 5). Nineteen (65.5%) of 29 patients with ESBL-producing *E. coli* infection had a recognized risk factor for antimicrobial drug resistance (Figure 2; online Technical Appendix Tables 2, 3). Sixteen (55.2%) had antimicrobial drug exposure within the previous 60 days. During the previous 90 days, 6 (20.7%) had healthcare-setting exposure and 4 (13.8%) had travel outside North America. We found ESBL-producing *E. coli* infection associated with complicated infection, prior antimicrobial drug use, travel outside North America, and prior UTI resulting from a fluoroquinolone- or ceftriaxone-resistant organism. Among 37 isolates that grew other *Enterobacteriaceae*, including *Klebsiella pneumoniae*, 1 (2.7%) was ESBL producing. Among 29 ESBL-producing *E. coli* isolates, susceptibility rates to other antimicrobial drugs were 41.4% to TMP/SMX, 18.5% to ciprofloxacin, 21.7% to levofloxacin, 41.4% to gentamicin, and 100% to carbapenem. The prevalence of *E. coli* fluoroquinolone resistance correlated with the prevalence of ESBL-producing *E. coli* by site (Figure 3).

We further characterized 26 ESBL-producing *E. coli* isolates and 1 *K. pneumoniae* isolate. Among *E. coli* isolates,

Table 3. Antimicrobial drug resistance rates for *Escherichia coli* isolates from US emergency department patients with acute uncomplicated and complicated pyelonephritis, July 2013–December 2014*

Antimicrobial drug	Patients with antimicrobial drug-resistant isolates, no./no. tested (%)		
	Total, N = 453	Uncomplicated cases, n = 272	Complicated cases, n = 181
Trimethoprim/sulfamethoxazole	165/453 (36.4)	111/272 (40.8)	54/181 (29.8)
Ampicillin	259/453 (57.2)	152/272 (55.9)	107/181 (59.1)
Cefazolin	52/367 (14.2)	18/219 (8.2)	34/148 (23.0)
Ceftriaxone	35/453 (7.7)	7/272 (2.6)	28/181 (15.5)
Ciprofloxacin	48/397 (12.1)	15/237 (6.3)	33/160 (20.6)
Levofloxacin	33/325 (10.2)	10/195 (5.1)	23/130 (17.7)
Gentamicin	43/436 (9.9)	19/261 (7.3)	24/175 (13.7)
Imipenem	0/135 (0)	0/90 (0)	0/45 (0)
Ertapenem	0/201 (0)	0/111 (0)	0/90 (0)
Meropenem	0/161 (0)	0/96 (0)	0/65 (0)
Doripenem	0/139 (0)	0/74 (0)	0/65 (0)

*Denominators indicate number of isolates tested against a specific antimicrobial drug; the composition of testing panels varied by site.




Figure 1. Prevalence of fluoroquinolone-resistant *Escherichia coli* infection among emergency department patients with uncomplicated (U) and complicated (C) pyelonephritis by study site, United States, July 2013–December 2014. Study sites are listed in the online Technical Appendix (<http://wwwnc.cdc.gov/EID/article/22/9/16-0148-Techapp1.pdf>); online Technical Appendix Tables 2 and 3 provide additional results on antimicrobial resistance rates. In vitro resistance to ciprofloxacin and/or levofloxacin is shown as % (no. of patients with a resistant isolate/total no. of patients tested)

PCR identified multiple ESBL types: 22 (84.6%) produced CTX-M-15 (16 [61.5%] produced only CTX-M-15; 6 [23.1%] produced CTX-M-15 and TEM-1); 2 (7.7%) produced CTX-M-27; 1 (3.8%) produced CTX-M-14; and 1 (3.8%) produced CTX-M-14 and TEM-1. The *K. pneumoniae* isolate produced SHV-1 and CTX-M-15 ESBL types. Sixteen (61.5%) of the *E. coli* isolates were clonal type O25b-ST131.

Among patients with an *E. coli* infection, 223 (49.2%) were discharged from the ED and 229 (50.6%) were admitted to the hospital; of these, 13 (5.8%) and 18 (7.9%), respectively, were treated with an antimicrobial drug that lacked in vitro activity against their infection. Of 53 patients with a fluoroquinolone-resistant and 29 with an ESBL-producing infection, 24 (45.3%) and 22 (75.0%), respectively, were initially treated with in vitro–inactive antimicrobial drugs. Among 29 patients with an ESBL infection, 9 (31.0%) were

discharged from the ED; an in vitro–inactive antimicrobial drug was initially prescribed to 7 (77.8%). Among 20 (69.0%) hospitalized patients with an ESBL infection, 15 (75.0%) were initially given an in vitro–inactive antimicrobial drug; 1 of those 15 patients was given gentamicin, 13 were given cephalosporin, and 1 was given both.

Discussion

For 2013–2014, we found that prevalence of *E. coli* fluoroquinolone resistance was >10% for patients with uncomplicated pyelonephritis at 2 of 10 sites and ≥20% for patients with complicated infections at 4 of 10 sentinel sites surveyed in the United States. *E. coli* fluoroquinolone resistance was particularly prevalent in groups with antimicrobial drug resistance risk. These rates exceed thresholds for the 2010 IDSA treatment guidelines, which recommend consideration of an

Table 4. Factors associated with fluoroquinolone resistance among 453 US emergency department patients with pyelonephritis caused by *Escherichia coli*, July 2013–December 2014*

Factor	Fluoroquinolone-resistance rate		Relative risk (95% CI)
	Factor present, no./total (%)	Factor absent, no./total (%)	
Complicated infection	36/181 (19.9)	17/272 (6.3)	3.2 (1.8–5.8)
Prior antimicrobial drugs taken			
Within past 60 d	24/94 (25.5)	29/359 (8.1)	3.2 (1.9–5.3)
Within past 2 d	9/27 (33.3)	44/426 (10.3)	3.2 (1.6–5.8)
Prior fluoroquinolone use			
Within past 60 d	12/19 (63.2)	41/434 (9.4)	6.7 (3.8–9.6)
Within past 2 d	6/8 (75.0)	47/445 (10.6)	7.1 (3.2–9.4)
IV antimicrobial drugs within past 30 d	6/26 (23.1)	47/425 (11.1)	2.1 (0.8–4.3)
LTC within past 90 d	1/3 (33.3)	52/450 (11.6)	2.9 (0.2–7.8)
Admitted to hospital within 90 d	11/42 (26.2)	42/411 (10.2)	2.6 (1.3–4.6)
Travel outside United States within past 90 d	5/17 (29.4)†	48/436 (11.0)	2.7 (1.0–5.5)
UTI resulting from fluoroquinolone-resistant <i>E. coli</i>			
Within past year	7/9 (77.8)	46/444 (10.4)	7.5 (3.7–9.6)
Within past 90 d	7/8 (87.5)	46/445 (10.3)	8.5 (4.3–9.8)
UTI resulting from ceftriaxone-resistant <i>E. coli</i>			
Within past year	5/6 (83.3)	48/447 (10.7)	7.8 (3.3–9.4)
Within past 90 d	5/5 (100.0)	48/448 (10.7)	9.3 (4.1–9.3)

*Denominators differ because factors have a different distribution among the patient population. IV, intravenous; LTC, residence in a long-term care facility; UTI, urinary tract infection.

†Of the 5 patients that traveled outside the United States, 3 traveled to Mexico or Central America and 2 traveled to Asia.




Figure 2. Prevalence of extended-spectrum β -lactamase-producing *Escherichia coli* infection among patients with uncomplicated (U) and complicated (C) pyelonephritis, by study site, United States, July 2013–December 2014. Study sites are listed in the online Technical Appendix (<http://wwwnc.cdc.gov/EID/article/22/9/16-0148-Techapp1.pdf>); online Technical Appendix Tables 2 and 3 provide additional results on antimicrobial resistance rates.

additional antimicrobial drug of a different class and other agents (9). Data from a similar study we conducted during 2000–2004 (15) indicate that, among all healthcare-seeking ED patients with acute pyelonephritis, the prevalence of fluoroquinolone-resistant *E. coli* increased from 3.9% during 2000–2004 to 11.7% during 2013–2014. During 2000–2004, we found no infections caused by ESBL-producing bacteria. As in other parts of the world, ESBL-producing *Enterobacteriaceae* are emerging among patients with community-acquired UTI in the United States. For patients with uncomplicated and complicated pyelonephritis caused by *E. coli*, we found that 2.6% and 12.2%, respectively, had infection caused by an ESBL-producing organism; rates were even higher for patients with risk factors. The globally disseminated, multidrug-resistant clone ST131, which produces CTX-M-15

β -lactamase, accounted for 85.2% of these infections. Of ESBL-infected patients, about one third lacked traditional antimicrobial resistance risk factors (i.e., antimicrobial drug or healthcare-setting exposure or international travel), suggesting that these isolates are now endemic in some US communities. Among ESBL-infected patients, about three quarters were initially treated with an antimicrobial drug lacking in vitro activity, including the sickest patients who required hospitalization. We did not collect outcome data, but lack of in vitro activity of the antimicrobial drug used for treatment has been associated with relatively poor response rates among patients with pyelonephritis (1,10,11).

Previous surveys have suggested that *E. coli* fluoroquinolone resistance rates are increasing in the United States. Among outpatients seeking care at 30 US centers during 2003–2004, 59 (6.8%) of 862 *E. coli* isolates were resistant to ciprofloxacin (2). Another analysis of >12 million urine specimens from US outpatient centers found that the *E. coli* fluoroquinolone resistance rate increased from 3.0% in 2000 to 17.1% in 2010 (3). Such laboratory-based resistance surveillance data may exaggerate the prevalence of resistance because patients for whom cultures are performed would be expected to have received prior therapy and to have had healthcare exposure more frequently than patients without cultures. Isolate-driven studies require retrospective review of records, which have missing and inaccurate data; also, uncertainty may exist regarding whether a specimen is from a patient with an actual clinical infection, rather than being a colonized or contaminated specimen. In routine practice, providers typically estimate local resistance rates on the basis of an antibiogram published by the local hospital laboratory. Resistance rates determined from antibiograms are prone to bias and indicate only whether the specimen was obtained from an outpatient or inpatient location.

In contrast, we conducted syndromic surveillance of patients who sought care at a geographically diverse network




Figure 3. Prevalence of fluoroquinolone-resistant and ESBL-producing *Escherichia coli* infections among patients with uncomplicated and complicated pyelonephritis, by study site, United States, July 2013–December 2014. Each dot indicates a study site; the line to show the general trend between fluoroquinolone resistance and ESBL-producing *E. coli* was generated by using simple linear regression. ESBL, extended spectrum β -lactamase.

Table 5. Factors associated with ESBL production among 453 US emergency department patients with pyelonephritis caused by *Escherichia coli*, July 2013–December 2014*

Factor	ESBL-producing <i>E. coli</i> rate		Relative risk (95% CI)
	Factor present, no./total (%)	Factor absent, no./total (%)	
Age >65 y	4/22 (18.2)	25/431 (5.8)	3.1 (0.96–8.1)
Complicated infection	22/181 (12.2)	7/272 (2.6)	4.7 (2.0–12.0)
Prior antimicrobial drugs			
Within past 60 d	16/94 (17.0)	13/359 (3.6)	4.7 (2.2–10.0)
Within past 2 d	4/27 (14.8)	25/426 (5.9)	2.5 (0.8–6.7)
IV antimicrobial drugs taken within past 30 d	4/26 (15.4)	25/425 (5.9)	2.6 (0.8–6.9)
LTC within past 90 d	1/3 (33.3)	28/450 (6.2)	5.4 (0.3–14.9)
Hospital admittance within past 90 d	5/42 (11.9)	24/411 (5.8)	2.0 (0.7–5.2)
Travel outside United States within past 90 d	4/17 (23.5)†	25/436 (5.7)	4.1 (1.3–10.1)
UTI caused by fluoroquinolone-resistant <i>E. coli</i>			
Within past year	5/9 (55.6)	24/444 (5.4)	10.3 (3.8–17.5)
Within past 90 d	5/8 (62.5)	24/445 (5.4)	11.6 (4.4–18.3)
UTI caused by ceftriaxone-resistant <i>E. coli</i>			
Within past year	5/6 (83.3)	24/447 (5.4)	15.5 (6.2–19.2)
Within past 90 d	5/5 (100.0)	24/448 (5.4)	18.7 (8.0–18.7)
Fluoroquinolone resistance	24/53 (45.3)	5/400 (1.3)	36.2 (14.2–104.7)

*Denominators differ because factors have a different distribution among the patient population. ESBL, extended spectrum β -lactamase; IV, intravenous; LTC, residence in a long-term care facility; UTI, urinary tract infection.

†Of these 4 patients who traveled to other regions, 3 traveled to Mexico or Central America and 1 traveled to Asia.

of US EDs. We studied acute pyelonephritis because it is a distinct clinical syndrome for which cultures are routinely obtained and because isolates grown are less likely to be contaminants or colonizers, compared with those from patients with suspected cystitis. Historical data were obtained by real-time patient interviews, enabling accurate classification of complicated and uncomplicated pyelonephritis and ascertainment of antimicrobial drug resistance risk factors. To identify biases, we compared characteristics of enrolled and nonenrolled qualifying patients and found their characteristics to be similar, suggesting the validity of our sampling. Consequently, our data and that of other studies indicate that, in some parts of the United States, the rate of *E. coli* fluoroquinolone resistance among uropathogens is >10% among patients with uncomplicated pyelonephritis and >20% among those with complicated infections. However, variability exists; among patients with uncomplicated pyelonephritis, 3 of 10 sites had fluoroquinolone resistance rates <5%. Consistent with findings of previous investigations, we found *E. coli* fluoroquinolone resistance associated with complicated infection, prior use of antimicrobial drugs and fluoroquinolone, hospitalization, and prior UTI caused by a fluoroquinolone- or ceftriaxone-resistant organism (16,17).

By using active, prospective surveillance, we found that ESBL-producing *E. coli* infections have now emerged to a considerable degree among patients with clinically confirmed community-acquired infections in parts of the United States, including among persons lacking commonly recognized antimicrobial drug resistance risk factors. This new observation is not unexpected, given the reported epidemiology of ESBL-producing *Enterobacteriaceae* infections in communities outside North America. CTX-M enzymes are currently the most prevalent ESBL types worldwide. The ST131 clone is largely responsible for the international

epidemic caused by CTX-M-15–producing *E. coli*, including infections seen in the United States (7,18,19).

A few US laboratory-based surveillance studies have reported community-acquired ESBL infections. Peirano et al. (19) described ESBL-producing *E. coli* isolates from 30 community-dwelling patients at 5 Chicago-area hospitals during 2008. These ESBL-producing strains represented 2%–8% of *E. coli* isolates at each hospital. Khawcharoenporn et al. (20) reported that \approx 5% of *Enterobacteriaceae* isolates from ED patients with presumed UTI during 2008–2009 were ESBL-producing, although specific risk data were not provided. Doi et al. (7) reviewed records of patients with cultures that grew ESBL-producing *E. coli* isolates at 1 hospital in each of 5 US cities during 2009–2010. Among 13,270 *E. coli* isolates, 523 (3.9%) were ESBL producing. Of the 291 patients infected or colonized with ESBL-producing *E. coli* as outpatients, infections of 107 (36.8%) were thought to be community associated. Community ESBL-producing *E. coli* isolates were resistant to multiple agents: 87.5% to ciprofloxacin or levofloxacin and 39.4% to gentamicin. All isolates from that study were susceptible to a carbapenem; we also found that all ESBL-producing isolates in our investigation were susceptible to a carbapenem.

Studies from outside North America have identified several characteristics associated with ESBL infection, such as recurrent and complicated UTI; advanced age; recent hospitalization; use of a β -lactam or fluoroquinolone; travel to Asia, Middle East, or Africa; and fresh water swimming (5,21–23). Banerjee et al. (23) conducted a case–control study among adults with *E. coli* clinical isolates cultured in the Chicago area and found that ESBL infection was associated with travel to India, ciprofloxacin use, and age. We found ESBL-producing *E. coli* infection associated with complicated infection, prior antimicrobial drug use, travel

outside North America, and prior UTI resulting from fluoroquinolone- or ceftriaxone-resistant infection. The importance of investigating past susceptibility data when considering empirical treatment is highlighted by our observation that both fluoroquinolone resistance and ESBL-production were associated with previous resistant infections.

Our study has limitations. We were unsuccessful in enrolling all consecutive patients, which may have introduced bias in our selection of patients. However, our audit of eligible case-patients showed similarity of enrolled and non-enrolled patients, including their *E. coli* antimicrobial drug susceptibility rates; furthermore, most (>97%) enrolled patients had urine cultures collected, reducing potential bias. The prevalence of ESBL-producing strains may have been underestimated because we did not use ESBL-selective media and used only ceftriaxone instead of several advanced-generation cephalosporins to screen for presence of ESBL-producing strains. However, this method enabled us to have greater site participation; furthermore, screening isolates with a ceftriaxone MIC >1 µg/mL has been reported to have a sensitivity >98% on the basis of phenotypic testing (24). In addition, some patients may not have had pyelonephritis if a contaminated specimen was misinterpreted as noncontaminated, although >97% of patients had urine collected by a technique that minimizes contamination (i.e., clean catch, urethral catheterization, or suprapubic aspiration), and the diagnosis of pyelonephritis was further supported by clinical assessment. Our definition of confirmed infection as growth of 1 uropathogen at >10⁴ CFU/mL may have missed some cases of pyelonephritis, although only ≈5% grew a single uropathogen at <10⁴ CFU/mL or grew >1 uropathogen at >10⁴ CFU/mL. Our hospitals were large US urban centers and may not represent patients in other settings, emphasizing the importance of local surveillance.

IDSA treatment guidelines for acute uncomplicated pyelonephritis recommend that, if the fluoroquinolone-resistance rate is >10%, then in addition to a fluoroquinolone, an agent of another class (i.e., ceftriaxone or gentamicin) should be administered (9). Our findings indicate that fluoroquinolone resistance rates for *E. coli* are approaching or exceed this threshold for patients with uncomplicated pyelonephritis in many parts of the United States. For uncomplicated cystitis, the guidelines recommend alternative agents if the resistance rate is >20%, which is the current situation for fluoroquinolones in many settings for patients with complicated pyelonephritis. Unfortunately, we found that only one half to two thirds of fluoroquinolone-resistant *E. coli* isolates were susceptible to ceftriaxone or gentamicin. Rates of fluoroquinolone-resistant and ESBL-producing *E. coli* infections correlate to geographic location. Prior exposure to antimicrobial drugs or a healthcare setting, travel outside the United States, and a history of an antimicrobial drug-resistant infection substantially increases the chance that a person will have a

current fluoroquinolone-resistant or ESBL-producing *E. coli* infection. Therefore, in settings with high fluoroquinolone resistance rates, in settings where ESBL-producing *Enterobacteriaceae* infections have emerged, or among persons with antimicrobial drug resistance risk factors (especially patients with or at risk for severe sepsis), healthcare providers should consider empirical treatment with a carbapenem or another agent found to be consistently active on the basis of the local antibiogram. In this study, ≈50% of patients with pyelonephritis were managed as outpatients. Currently, no oral antimicrobial drugs with consistent in vitro activity are available for empirical treatment of pyelonephritis caused by ESBL-producing *E. coli* uropathogens. Our findings, including the variability in the prevalence of resistance by site, show that increased local efforts to enhance surveillance for antimicrobial drug resistance are necessary to best inform treatment decisions. Furthermore, availability of new antimicrobial drugs must be expedited.

Acknowledgments

We thank Robert Badal, Brian Johnson, and Krystyna Kazmierczak at the International Health Management Associates, Inc. (IHMA). We also thank Ellen Jo Baron, Kavitha Pathmarajah, Britany Zeglin, Mary Mulrow, Shelley Fuentes, Laurie Kemble, Danielle Beckham, Niccole Neal, Ada Rubin, Sarah Usher, Stephen Peterson, Lila Steinberg, Christine Sayegh, Kimberly Dehnkamp, Kamil Narayan, Silas Bussman, Richard Dwyer, and the residents and staff at the participating emergency departments.

We also thank the site investigators of the EMERGENCY ID NET Study Group: Fredrick M. Abrahamian, Olive View–University of California, Los Angeles Medical Center, Sylmar, CA, USA; Johanna Moore, Hennepin County Medical Center, Minneapolis, MN, USA; Jon Femling, University of New Mexico Health Sciences Center, Albuquerque, NM, USA; William K. Chiang, Bellevue Hospital Center, New York, NY, USA; Frank LoVecchio, Maricopa Medical Center, Phoenix, AZ, USA; Jon Jui, Oregon Health & Science University, Portland, OR, USA; Manish Garg, Temple University School of Medicine, Philadelphia, PA, USA; Mark T. Steele, University of Missouri–Kansas City, Kansas City, MO, USA; Sukhjit S. Takhar, Brigham and Women's Hospital, Boston, MA, USA; and Richard Rothman, The Johns Hopkins Hospital, Baltimore, MD, USA.

This research was supported by a grant from the US Centers for Disease Control and Prevention, Cooperative Agreement Number U01CK000176. Confirmation of ESBL production and molecular characterization was completed by the IHMA laboratory and funded by Merck & Co., Inc.

Dr. Talan is professor of medicine in residence (emeritus) at the David Geffen School of Medicine at UCLA in Los Angeles. His research focuses on emergency department-based surveillance

and epidemiologic research of emerging infections and clinical investigations of acute infectious diseases.

References

1. Talan DA, Stamm WE, Hooton TM, Moran GJ, Burke T, Iravani A, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. *JAMA*. 2000;283:1583–90. <http://dx.doi.org/10.1001/jama.283.12.1583>
2. Zhanel GG, Hisanaga TL, Laing NM, DeCorby MR, Nichol KA, Weshnoweski B, et al.; NAUTICA Group. Antibiotic resistance in *Escherichia coli* outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). *Int J Antimicrob Agents*. 2006;27:468–75. <http://dx.doi.org/10.1016/j.ijantimicag.2006.02.009>
3. Sanchez GV, Master RN, Karlowsky JA, Bordon JM. In vitro antimicrobial resistance of urinary *Escherichia coli* isolates among U.S. outpatients from 2000 to 2010. *Antimicrob Agents Chemother*. 2012;56:2181–3. <http://dx.doi.org/10.1128/AAC.06060-11>
4. Dalhoff A. Global fluoroquinolone resistance epidemiology and implications for clinical use. *Interdiscip Perspect Infect Dis*. 2012;2012:976273.
5. Johnson SW, Anderson DJ, May DB, Drew RH. Utility of a clinical risk factor scoring model in predicting infection with extended-spectrum β -lactamase-producing *enterobacteriaceae* on hospital admission. *Infect Control Hosp Epidemiol*. 2013;34:385–92. <http://dx.doi.org/10.1086/669858>
6. Hayakawa K, Gattu S, Marchaim D, Bhargava A, Palla M, Alshabani K, et al. Epidemiology and risk factors for isolation of *Escherichia coli* producing CTX-M-type extended-spectrum β -lactamase in a large U.S. Medical Center. *Antimicrob Agents Chemother*. 2013;57:4010–8. <http://dx.doi.org/10.1128/AAC.02516-12>
7. Doi Y, Park YS, Rivera JI, Adams-Haduch JM, Hingwe A, Sordillo EM, et al. Community-associated extended-spectrum β -lactamase-producing *Escherichia coli* infection in the United States. *Clin Infect Dis*. 2013;56:641–8. <http://dx.doi.org/10.1093/cid/cis942>
8. Peirano G, van der Bij AK, Gregson DB, Pitout JD. Molecular epidemiology over an 11-year period (2000 to 2010) of extended-spectrum β -lactamase-producing *Escherichia coli* causing bacteremia in a centralized Canadian region. *J Clin Microbiol*. 2012;50:294–9. <http://dx.doi.org/10.1128/JCM.06025-11>
9. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al.; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Infect Dis*. 2011;52:e103–20. <http://dx.doi.org/10.1093/cid/ciq257>
10. Shin J, Kim J, Wie SH, Cho YK, Lim SK, Shin SY, et al. Fluoroquinolone resistance in uncomplicated acute pyelonephritis: epidemiology and clinical impact. *Microb Drug Resist*. 2012;18:169–75. <http://dx.doi.org/10.1089/mdr.2011.0139>
11. Lee S, Song Y, Cho SH, Kwon KT. Impact of extended-spectrum beta-lactamase on acute pyelonephritis treated with empirical ceftriaxone. *Microb Drug Resist*. 2014;20:39–44. <http://dx.doi.org/10.1089/mdr.2013.0075>
12. Talan DA, Moran GJ, Mower W, Newdow M, Ong S, Slutsker L, et al.; The EMERGENCY ID NET Study Group. EMERGENCY ID NET: an emergency department-based emerging infections sentinel network. *Ann Emerg Med*. 1998;32:703–11. [http://dx.doi.org/10.1016/S0196-0644\(98\)70071-X](http://dx.doi.org/10.1016/S0196-0644(98)70071-X)
13. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement. CLSI document M100–S22. Wayne (PA): The Institute; 2012.
14. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42:377–81. <http://dx.doi.org/10.1016/j.jbi.2008.08.010>
15. Talan DA, Krishnadasan A, Abrahamian FM, Stamm WE, Moran GJ; EMERGENCY ID NET Study Group. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant *Escherichia coli* infection among emergency department patients with pyelonephritis. *Clin Infect Dis*. 2008;47:1150–8. <http://dx.doi.org/10.1086/592250>
16. Bedoin M, Cazorla C, Lucht F, Berthelot P, Boyer M, Carricajo A, et al. Risk factors for quinolone-resistance in women presenting with *Escherichia coli* acute pyelonephritis. *Med Mal Infect*. 2014;44:206–16. <http://dx.doi.org/10.1016/j.medmal.2014.02.003>
17. van der Starre WE, van Nieuwkoop C, Paltansing S, van't Wout JW, Groeneveld GH, Becker MJ, et al. Risk factors for fluoroquinolone-resistant *Escherichia coli* in adults with community-onset febrile urinary tract infection. *J Antimicrob Chemother*. 2011;66:650–6. <http://dx.doi.org/10.1093/jac/dkq465>
18. Johnson JR, Urban C, Weissman SJ, Jorgensen JH, Lewis JS II, Hansen G, et al.; AMERECUS Investigators. Molecular epidemiological analysis of *Escherichia coli* sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum- β -lactamase-producing *E. coli* from the United States, 2000 to 2009. *Antimicrob Agents Chemother*. 2012;56:2364–70. <http://dx.doi.org/10.1128/AAC.05824-11>
19. Peirano G, Costello M, Pitout JD. Molecular characteristics of extended-spectrum beta-lactamase-producing *Escherichia coli* from the Chicago area: high prevalence of ST131 producing CTX-M-15 in community hospitals. *Int J Antimicrob Agents*. 2010;36:19–23. <http://dx.doi.org/10.1016/j.ijantimicag.2010.02.016>
20. Khawcharoenporn T, Vasoo S, Singh K. Urinary tract infections due to multidrug-resistant *Enterobacteriaceae*: prevalence and risk factors in a Chicago emergency department. *Emerg Med Int*. 2013;2013:258517.
21. Søråas A, Sundsfjord A, Sandven I, Brunborg C, Jennum PA. Risk factors for community-acquired urinary tract infections caused by ESBL-producing *enterobacteriaceae*—a case-control study in a low prevalence country. *PLoS One*. 2013;8:e69581. <http://dx.doi.org/10.1371/journal.pone.0069581>
22. Azap OK, Arslan H, Serefhanoglu K, Colakoglu S, Erdogan H, Timurkaynak F, et al. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic *Escherichia coli* isolated from community-acquired urinary tract infections. *Clin Microbiol Infect*. 2010;16:147–51. <http://dx.doi.org/10.1111/j.1469-0691.2009.02941.x>
23. Banerjee R, Strahilevitz J, Johnson JR, Nagwekar PP, Schora DM, Shevri I, et al. Predictors and molecular epidemiology of community-onset extended-spectrum β -lactamase-producing *Escherichia coli* infection in a Midwestern community. *Infect Control Hosp Epidemiol*. 2013;34:947–53. <http://dx.doi.org/10.1086/671725>
24. Huang Y, Carroll KC, Cosgrove SE, Tamma PD. Determining the optimal ceftriaxone MIC for triggering extended-spectrum β -lactamase confirmatory testing. *J Clin Microbiol*. 2014;52:2228–30. <http://dx.doi.org/10.1128/JCM.00716-14>

Address for correspondence: David A. Talan, Olive View–UCLA Medical Center, 14445 Olive View Dr, North Annex, Sylmar, CA 91342, USA; email: idnet@ucla.edu

Fluoroquinolone-Resistant and Extended-Spectrum β -Lactamase–Producing *Escherichia coli* infections in Patients with Pyelonephritis, United States

Technical Appendix

Methods and Materials

Study Sites

The study was conducted at the following emergency department sites in the United States: Olive View–University of California, Los Angeles Medical Center, Los Angeles, CA; Hennepin County Medical Center, Minneapolis, MN; University of New Mexico Health Sciences Center, Albuquerque, NM; Bellevue Hospital Center, New York, NY; Maricopa Medical Center, Phoenix, AZ; Oregon Health & Science University, Portland, OR; Temple University School of Medicine, Philadelphia, PA; University of Missouri–Kansas City, Kansas City, MO; Brigham and Women’s Hospital, Boston, MA; The Johns Hopkins Hospital, Baltimore, MD.

Confirmation of Extended-Spectrum β -Lactamase Production and Molecular Characterization

Study sites referred ceftriaxone-nonsusceptible (i.e., MIC >1 $\mu\text{g/mL}$) *Enterobacteriaceae* isolates to the laboratory at International Health Management Associates, Inc. ([IHMA] Schaumburg, IL, USA) for specie identification. IHMA confirmed specie identification by matrix-assisted laser desorption ionization time of flight mass spectrometry (Bruker Daltronics, Bremen, Germany). Temple University School of Medicine referred all *Escherichia coli* isolates. MICs to ceftriaxone were determined by broth microdilution by using custom-manufactured dehydrated panels (MicroScan, Siemens Medical Solutions Diagnostics, West Sacramento, CA, USA), following Clinical and Laboratory Standards Institute guidelines (1).

All *E. coli*, *Klebsiella pneumoniae*, and *Proteus mirabilis* isolates with ceftriaxone MIC values $>1 \mu\text{g/mL}$ were further screened at IHMA for extended-spectrum β -lactamase (ESBL) activity by using a disk diffusion assay testing cefotaxime (30 μg), cefotaxime/clavulanic acid (30/10 μg), ceftazidime (30 μg), and ceftazidime/clavulanic acid (30/10 μg) disks (BBL Sensi-Disc, Becton Dickinson, Franklin Lakes, NJ, USA). An isolate was confirmed as phenotypically ESBL positive if the inhibition zone diameter of the combination disk increased $\geq 5 \text{ mm}$, compared with that of only cephalosporin (1).

All isolates subjected to the phenotypic ESBL test were screened for the presence of β -lactamase genes encoding ESBLs (TEM-, SHV-, CTX-M-, VEB-, PER-, GES-type), original-spectrum β -lactamases (TEM-1, SHV-1, SHV-11), plasmid-mediated AmpC β -lactamases (ACC-, ACT-, CMY-, DHA-, FOX-, MIR-, MOX-type), and carbapenemases (KPC-, OXA-48-, IMP-, VIM-, NDM-, SPM-type) by using previously described multiplex PCR assays (2). Enzyme variants were identified by DNA sequencing and comparison with sequences in public databases maintained by the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov) and the Lahey Clinic (www.lahey.org/studies). *E. coli* isolates with ceftriaxone MIC values $>1 \mu\text{g/mL}$ were screened by PCR for the presence of sequence type 131-associated single-nucleotide polymorphisms in *mdh* and *gyrB* (3) and were screened separately for O25b- and O16-specific *rfb* variants (4). Sequence type 131 control strains were generously provided by D. Hoban and K. Nichol at the University of Manitoba (Winnipeg, Manitoba, Canada). Three *E. coli* isolates identified as ESBL producers at the Temple University site were not saved and sent to the IHMA laboratory but were confirmed to be ESBL by the Phoenix ESBL test (Becton Dickinson).

Audit Comparing Enrolled and Nonenrolled Cases

All sites conducted an audit to compare characteristics of enrolled and nonenrolled eligible patients. Site investigators screened emergency department (ED) patient logs to find patients with ED discharge of pyelonephritis (i.e., International Classification of Diseases, Ninth Revision, code 590.8 [pyelonephritis, unspecified]) and a documented temperature $\geq 38.0^\circ\text{C}$; they then reviewed medical records for these patients. Patients meeting study eligibility criteria had the following data collected: age, sex, ED disposition (i.e., discharged home, admitted to ward or ICU, admitted to ED observation, or left ED against medical advice), proportion pathogen and *E.*

coli growth, and *E. coli* susceptibility to trimethoprim/sulfamethoxazole, ceftriaxone, and fluoroquinolones.

References

1. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. CLSI document M100-S25. Wayne (PA): Clinical and Laboratory Standards Institute; Jan 2015.
2. Lob SH, Kazmierczak KM, Badal RE, Hackel MA, Bouchillon SK, Biedenbach DJ, et al. Trends in susceptibility of *Escherichia coli* from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013. *Antimicrob Agents Chemother*. 2015;59:3606–10. <http://dx.doi.org/10.1128/AAC.05186-14>
3. Johnson JR, Menard M, Johnston B, Kuskowski MA, Nichol K, Zhanel GG. Epidemic clonal groups of *Escherichia coli* as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. *Antimicrob Agents Chemother*. 2009;53:2733–9. <http://dx.doi.org/10.1128/AAC.00297-09>
4. Johnson JR, Clermont O, Johnston B, Clabots C, Tchesnokova V, Sokurenko E, et al. Rapid and specific detection, molecular epidemiology, and experimental virulence of the O16 subgroup within *Escherichia coli* sequence type 131. *J Clin Microbiol*. 2014;52:1358–65. <http://dx.doi.org/10.1128/JCM.03502-13>

Technical Appendix Table 1. Comparison of eligible enrolled and nonenrolled US emergency department patients, July 2013–December 2014*

Characteristic	Enrolled, no. (%) N = 817	Nonenrolled, no. (%) N = 414
Median age (range), y	37 (18–89)	37 (18–79)
Sex		
F	684 (83.7)	335/408 (82.1)
M	133 (16.3)	73/408 (17.9)
Hospitalized	478 (58.5)	200/411 (48.7)
Pathogen growth in urine culture	644 (78.8)	336 (81.2)
<i>E. coli</i> growth in urine culture	480 (58.8)	238 (57.4)
<i>E. coli</i> susceptible to TMP/SMX	308 (64.2)	164/248 (66.1)
<i>E. coli</i> susceptible to ceftriaxone	442/480 (92.1)	181/191 (94.8)
<i>E. coli</i> susceptible to levofloxacin	303/339 (89.4)	113/121 (93.4)
<i>E. coli</i> susceptible to ciprofloxacin	369/424 (87.0)	152/172 (88.4)

* Denominators are indicated if data were missing. TMP/SMX, trimethoprim-sulfamethoxazole.

Technical Appendix Table 2. *Escherichia coli* antimicrobial drug resistance rates among 272 US emergency department patients with uncomplicated pyelonephritis by study site, July 2013–December 2014

Site	Antimicrobial drug resistance, no./total tested (%)										
	Ampic	TMP/SMX	Genta	Cefaz	Ceftr	Cipro	Levof	Imipe	Ertap	Merop	Dorip
All sites	152/272 (55.9)	111/272 (40.8)	19/261 (7.3)	18/219 (8.2)	7/272 (2.6)	15/237 (6.3)	10/195 (5.1)	0/90 (0)	0/111 (0)	0/96 (0)	0/74 (0)
New York, NY	17/24 (70.8)	13/24 (54.2)	3/24 (12.5)	4/24 (16.7)	2/24 (8.3)	3/24 (12.5)	NA	0/24 (0)	NA	0/23 (0)	NA
Boston, MA	7/16 (43.8)	4/16 (25.0)	1/9 (11.1)	1/2 (50.0)	0/16 (0)	0/16 (0)	0/10 (0)	0/1 (0)	0/5 (0)	0/3 (0)	NA
Minneapolis, MN	7/21 (33.3)	5/21 (23.8)	1/21 (4.8)	NA	1/21 (4.8)	0/2 (0)	1/21 (4.8)	N/A	0/21 (0)	0/19 (0)	0/2 (0)
Baltimore, MD	6/13 (46.2)	5/13 (38.5)	0/13 (0)	1/13 (7.7)	0/13 (0)	3/13 (23.1)	NA	0/3 (0)	0/13 (0)	0/13 (0)	NA
Phoenix, AZ	16/22 (72.7)	12/22 (54.5)	0/22 (0)	0/4 (0)	0/22 (0)	1/22 (4.5)	1/22 (4.5)	NA	NA	NA	NA
Portland, OR	5/8 (62.5)	4/8 (50.0)	1/8 (12.5)	1/8 (12.5)	0/8 (0)	0/8 (0)	NA	NA	NA	NA	NA
Los Angeles, CA	44/71 (62.0)	32/71 (45.1)	9/71 (12.7)	5/71 (7.0)	3/71 (4.2)	4/71 (5.6)	4/71 (5.6)	N/A	0/71 (0)	NA	0/71 (0)
Philadelphia, PA	28/53 (52.8)	18/53 (34.0)	1/53 (1.9)	4/53 (7.5)	1/53 (1.9)	3/53 (5.7)	3/52 (5.8)	0/53 (0)	0/1 (0)	0/1 (0)	0/1 (0)
Kansas City, MO	9/19 (47.4)	8/19 (42.1)	1/19 (5.3)	1/19 (5.3)	0/19 (0)	0/3 (0)	1/19 (5.3)	N/A	NA	0/18 (0)	NA
Albuquerque, NM	13/25 (52.0)	10/25 (40.0)	2/21 (9.5)	1/25 (4.0)	0/25 (0)	1/25 (4.0)	NA	0/9 (18.2)	NA	0/19 (0)	NA

*Ampic, ampicillin; Cefaz, cefazolin; Ceftr, ceftriaxone; Cipro, ciprofloxacin; Dorip, doripenem; Ertap, ertapenem; Genta, gentamicin; Imipe, imipenem; Levof, levofloxacin; Merop, meropenem; NA, none tested; TMP/SMX, trimethoprim-sulfamethoxazole.

Technical Appendix Table 3. *Escherichia coli* antimicrobial-drug resistance rates among 181 US emergency department patients with complicated pyelonephritis by study site, July 2013–December 2014

Site	Antimicrobial drug resistance, no./total tested (%)										
	Ampic	TMP/SMX	Genta	Cefaz	Ceftr	Cipro	Levof	Imipe	Ertap	Merop	Dorip
All sites	107/181 (59.1)	54/181 (29.8)	24/175 (13.7)	34/148 (23.0)	28/181 (15.5)	33/160 (20.6)	23/130 (17.7)	0/45 (0)	0/90 (0)	0/65 (0)	0/65 (0)
New York, NY	12/21 (57.1)	4/21 (19.0)	4/21 (19.0)	8/21 (38.1)	4/21 (19.0)	7/21 (33.3)	1/1 (100.0)	0/21 (0)	NA	0/21 (0)	NA
Boston, MA	4/6 (66.7)	2/6 (33.3)	0/3 (0)	0/1 (0)	0/6 (0)	0/6 (0)	0/3 (0)	NA	NA	NA	NA
Minneapolis, MN	6/13 (46.2)	4/13 (30.8)	2/12 (16.7)	1/1 (100.0)	1/13 (7.7)	0/1 (0)	2/13 (15.4)	NA	0/12 (0)	0/12 (0)	0/1 (0)
Baltimore, MD	7/10 (70.0)	4/10 (40.0)	2/10 (20.0)	1/10 (10.0)	1/10 (10.0)	2/10 (20.0)	NA	0/4 (0)	0/10 (0)	0/10 (0)	NA
Phoenix, AZ	12/21 (57.1)	11/21 (52.4)	1/21 (4.8)	1/5 (20.0)	3/21 (14.3)	3/21 (14.3)	3/21 (14.3)	NA	0/1 (0)	0/1 (0)	NA
Portland, OR	6/8 (75.0)	2/8 (25.0)	2/8 (25.0)	4/8 (50.0)	2/8 (25.0)	4/8 (50.0)	0/1 (0)	NA	0/3 (0)	0/3 (0)	NA
Los Angeles, CA	45/64 (70.3)	19/64 (29.7)	9/64 (14.1)	15/64 (23.4)	13/64 (20.3)	13/64 (20.3)	13/64 (20.3)	NA	0/64 (0)	NA	0/64 (0)
Philadelphia, PA	8/18 (44.4)	4/18 (22.2)	2/18 (11.1)	3/18 (16.7)	3/18 (16.7)	3/18 (16.7)	3/18 (16.7)	0/18 (0)	NA	NA	NA
Kansas City, MO	3/9 (33.3)	2/9 (22.2)	1/9 (11.1)	0/9 (0)	0/9 (0)	NA	1/9 (11.1)	NA	NA	0/9 (0)	NA
Albuquerque, NM	4/11 (36.4)	2/11 (18.2)	1/9 (11.1)	1/11 (9.1)	1/11 (9.1)	1/11 (9.1)	NA	0/2 (0)	NA	0/9 (0)	NA

*Ampic, ampicillin; Cefaz, cefazolin; Ceftr, ceftriaxone; Cipro, ciprofloxacin; Dorip, doripenem; Ertap, ertapenem; Genta, gentamicin; Imipe, imipenem; Levof, levofloxacin; Merop, meropenem; NA, none tested; TMP/SMX, trimethoprim-sulfamethoxazole